Bristol Myers' stock decline in response to weak guidance is a gift to investors

Bristol Myers Stock Decline: A Buying Opportunity - PressReach

In recent trading sessions, Bristol Myers Squibb (NYSE:BMY) faced a notable decline in its stock price following the release of its latest financial guidance. While the company reported robust earnings, the forecast for upcoming quarters appeared less optimistic, causing investors to react with caution. Despite the initial market reaction, analysts suggest that this dip could present a valuable opportunity for long-term investors. One of the pri…

Bristol Myers’ stock decline in response to weak guidance is a gift to investors – DG Verifications & Stats

Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts’ estimates compiled by LSEG. Adjusted earnings per share (EPS) of $1.67 in the three months ended Dec. 31 topped estimates of $1.46, L…

Bristol Myers’ stock decline in response to weak guidance is a gift to investors – Sky News: The Latest News from the World

Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts’ estimates compiled by LSEG. Adjusted earnings per […]

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%

Bristol Myers Squibb (BMY) stock plunged early Thursday after the drugmaker reported adjusted earnings of $1.67 per share on $12.34 billion in fourth-quarter sales. ↑ X How To Buy Stocks: Flat Base Chart PatternOn average, analysts polled by FactSet expected Bristol Myers to earn $1.46 per share…

Bristol Myers forecasts 2025 revenue below estimates after strong quarter - Regional Media News

By Michael Erman (Reuters) -Bristol Myers Squibb on Thursday posted better-than-expected fourth-quarter earnings, but said its 2025 revenue would fall more sharply than Wall Street had forecast due to generic competition for some of its older drugs. Shares of the drugmaker fell nearly 4% to $57.33 before the bell. The company forecast 2025 revenue of around $45.5 billion, down from $48.3 billion in 2024 and below analyst expectations of $47.4 bi…

Bristol Myers, Kyowa Kirin disclose layoffs

Bristol Myers Squibb lays off 67 staffers in NJ: The company is letting go of 67 workers in Lawrence Township between April and December, according to a New Jersey WARN Notice ...